Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting

Resistance to second-generation androgen receptor (AR) antagonists such as enzalutamide is an inevitable consequence in patients with castration-resistant prostate cancer (CRPC). There are no effective therapeutic options for this recurrent disease. The expression of truncated AR variant 7 (AR-V7) h...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawant, Mithila, Mahajan, Kiran, Renganathan, Arun, Weimholt, Cody, Luo, Jingqin, Kukshal, Vandna, Jez, Joseph M., Jeon, Myung Sik, Zhang, Bo, Li, Tiandao, Fang, Bin, Luo, Yunting, Lawrence, Nicholas J., Lawrence, Harshani R., Feng, Felix Y., Mahajan, Nupam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259236/
https://www.ncbi.nlm.nih.gov/pubmed/35704598
http://dx.doi.org/10.1126/scitranslmed.abg4132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259236/
https://www.ncbi.nlm.nih.gov/pubmed/35704598
http://dx.doi.org/10.1126/scitranslmed.abg4132

Ejemplares similares